Preeclampsia Diagnostics Market : Global Share, Size, Growth, Trends & Outlook ( 2022 – 2032 )

Preeclampsia Diagnostics Market Insights:

Preeclampsia may be a pregnancy-related medical condition that affects around 5-8% of pregnant women. it's typically characterized by high vital signs and damage to organs, most ordinarily the liver and kidneys. Preeclampsia usually develops after 20 weeks of pregnancy and may affect both the mother and therefore the fetus. the precise explanation for preeclampsia isn't fully understood, but it's believed to be associated with problems with the placenta. during a normal pregnancy, the placenta provides oxygen and nutrients to the growing fetus, and waste products are removed through the mother's blood. However, in preeclampsia, the blood vessels within the placenta don't develop properly, which may cause reduced blood flow to the placenta and a build-up of waste products. This, in turn, can cause high vital signs and damage to organs.

Preeclampsia is often a significant complication and may cause significant morbidity and mortality for both the mother and therefore the baby if not properly managed. Several tests are used to diagnose preeclampsia, including:

Vital sign measurement: A big increase in vital signs is one of the most signs of preeclampsia.

Proteinuria: The presence of protein within the urine is another key indicator of preeclampsia which is detected through a urine test. 

Liver function tests: Preeclampsia can affect liver function, so liver enzymes could also be measured to assist diagnose the condition.

Coagulation tests: Preeclampsia also can affect the blood's ability to clot, so coagulation tests could also be conducted to assess this.

Ultrasound: An ultrasound could also be wont to assess the baby's growth and well-being, also on the search for signs of placental dysfunction, which may be a symbol of preeclampsia.

Preeclampsia Diagnostics Market Size and Share

The global preeclampsia diagnostics market was valued at $1.3 billion in 2020 and is predicted to succeed at $2.7 billion by 2032, growing at a compound annual rate of growth (CAGR) of 6.4% during the forecast period of 2022 to 2032. The blood tests segment accounted for the most important share of the market in 2020 thanks to their ability to detect preeclampsia early and monitor its progression. North America accounted for the most important share of the market in 2020 thanks to the high prevalence of preeclampsia within the region, the supply of advanced diagnostic technologies, and therefore the presence of a key market player. Factors driving the expansion of the market include the increasing incidence of preeclampsia, the rising demand for early and accurate diagnosis, and therefore the growing focus of market players on the event of advanced diagnostic technologies.

The key players within the global preeclampsia diagnostics market include PerkinElmer, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Inc., Sera Prognostics, Inc., Quidel Corporation, Beckman Coulter, Inc., Alere Inc., and Bayer AG, among others.

Preeclampsia Diagnostics Market Latest Trends

Development of latest diagnostic technologies: There's ongoing research and development of the latest diagnostic technologies for preeclampsia, like non-invasive tests which will be conducted at an earlier stage of pregnancy.

Increased specialization in early diagnosis and prevention: There's a growing recognition of the importance of early diagnosis and prevention of preeclampsia, as this will help to enhance outcomes for both the mother and therefore the baby.

Increased use of telemedicine: The COVID-19 pandemic has led to a big increase in the use of telemedicine, including for the diagnosis and management of preeclampsia.

Growing awareness of the risks of preeclampsia: There has been a rise in public awareness of the risks related to preeclampsia, which can drive demand for diagnostic testing.

Growing prevalence of gestational hypertension: The prevalence of gestational hypertension (high vital signs during pregnancy) is increasing, which can cause a rise in the demand for preeclampsia diagnostics.

Preeclampsia Diagnostics Market Key Drivers:

Several factors are driving the growth of the preeclampsia diagnostics market:

Technological advancements: Market players that specialize in the event of advanced diagnostic technologies like biomarker-based tests and point-of-care testing (POCT) to enhance the accuracy and speed of diagnosis.

Rising awareness: Governments, healthcare organizations, and non-profit organizations are increasing awareness about preeclampsia and its diagnosis, resulting in increased demand for diagnostic tests. 

Increasing prevalence of preeclampsia: The prevalence of preeclampsia is increasing globally, particularly in developing countries, which is driving demand for diagnostic tools and coverings.

Increasing healthcare spending: There's generally increasing healthcare spending globally, which is driving demand for a good range of diagnostic and management tools, including those for preeclampsia.

Increasing specialization in maternal and child health: There's a growing specialization in improving maternal and child health globally, which is driving demand for diagnostic and management tools for conditions like preeclampsia.

Increasing focus on emerging markets: The preeclampsia diagnostics market is expanding into emerging markets like Asia-Pacific and Latin America, where there's a high burden of preeclampsia and an increasing demand for diagnostic tests.

Adoption of non-invasive diagnostic tests: Non-invasive diagnostic tests like blood tests and urine tests are gaining popularity over invasive tests thanks to their simple use and fewer risk of complications.

Growing demand for personalized medicine: The trend towards personalized medicine is additionally impacting the preeclampsia diagnostics market, with the event of diagnostic tests which will predict a woman's risk of developing preeclampsia and supply personalized treatment options.

Collaborations and partnerships: Market players are increasingly collaborating and partnering with academic and research institutions to develop new diagnostic technologies and expand their market presence.

Preeclampsia Diagnostics Market Segmentation:

The global market for preeclampsia diagnostics can be segmented in many ways, such as:

Type of diagnostic test: Blood Pressure Measurement, Proteinuria Testing, Ultrasound, Liver Function Tests

By end user: Hospitals, Clinics, Laboratories

By geography: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

By stage of pregnancy: Early Pregnancy, Later Stages

Preeclampsia Diagnostics Market Regional Synopsis

The largest market for preeclampsia diagnostics with a market size of $561.7 million in 2020 and a growth projected at a CAGR of 6.1% during the forecast period of 2021-2028, North America is expected to continue its dominance with the high prevalence of preeclampsia in the region, coupled with the presence of key market players and advanced diagnostic technologies. The second-largest market for preeclampsia diagnostics with a market size of $350.2 million in 2020 and a growth projected at a CAGR of 6.3% during the forecast period of 2021-2028, Europe is also expected to witness significant growth during the forecast period. The increasing awareness about preeclampsia and the growing demand for non-invasive diagnostic tests are driving market growth in the region.

The fastest-growing market for preeclampsia diagnostics with a market size of $218.3 million in 2020 and a growth projected at a CAGR of 7.0% during the forecast period of 2021-2028, Asia-Pacific is expected to witness significant growth during the forecast period. The region has a high burden of preeclampsia, and the increasing demand for early and accurate diagnosis is driving the market growth. Additionally, the growing focus of market players on the development of affordable and accessible diagnostic technologies is expected to further drive market growth.

Latin American market with a market size of $92.6 million in 2020 and growth projected at a CAGR of 6.5% during the forecast period of 2021-2028 is expected to witness steady growth due to the increasing awareness about preeclampsia and the growing demand for diagnostic tests. The Middle East and African region have a relatively low burden of preeclampsia, but the increasing awareness about the condition and the growing demand for diagnostic tests are expected to drive market growth. A moderate-growth market for preeclampsia diagnostics, with a market size of $89.2 million in 2020 and a projected CAGR of 5.9% during the forecast period of 2021-2028.

Preeclampsia Diagnostics Market Key Challenges:

There are several challenges facing the preeclampsia diagnostics market.

Complex diagnosis: Preeclampsia may be a complex condition that will be challenging to diagnose, particularly in its early stages. this will end in missed or delayed diagnoses, which may cause serious complications.

High Cost: The value of diagnostic tests and coverings for preeclampsia is often a barrier for a few patients, particularly in low-income countries.

Lack of standardization: There's no standard diagnostic assay for preeclampsia, which may make it difficult to accurately diagnose the condition. This lack of standardization also can cause variability within the results of various diagnostic tests, making it challenging to match results across different tests and laboratories.

Limited access to healthcare: In some regions, access to healthcare could also be limited, which may make it difficult for pregnant women to urge the care they have to manage preeclampsia.

Limited availability of diagnostic tools: In some regions, access to diagnostic tools for preeclampsia could also be limited, which may make it difficult to diagnose and manage the condition effectively.

Limited awareness: Preeclampsia may be a condition that's not widely known or understood, particularly in developing countries. This lack of awareness may result in a delay in diagnosis and treatment, which may be life-threatening for both the mother and therefore the baby.

Limited research on preeclampsia: there's still a scarcity of understanding of the underlying causes of preeclampsia, which may make it difficult to develop new diagnostic and management tools.

Technological limitations: Some diagnostic tests for preeclampsia require sophisticated technology, which can not be available altogether in healthcare settings. this will limit access to those tests in certain regions.

Preeclampsia Diagnostics Market Key Industry Developments:

There have been several recent developments in the industry for preeclampsia diagnostics:

Development of non-invasive tests: There has been a push to develop non-invasive diagnostic tests for preeclampsia, as current tests are often invasive and should not be feasible to conduct within the early stages of pregnancy.

Development of latest treatment options: there's ongoing research and development of the latest treatments for preeclampsia, including medications and therapies which will help to manage the condition and improve outcomes.

Advances in diagnostic technologies: There are significant advancements in diagnostic technologies for preeclampsia, including the utilization of biomarkers like placental protein (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT-1) to enhance diagnosis and predict disease severity.

Increased specialization in early detection: Early detection of preeclampsia is critical for improving outcomes for both the mother and therefore the baby. there's a growing specialization in developing diagnostic tests which will detect preeclampsia in its early stages before it becomes a life-threatening condition.

Development of point-of-care tests: there's a requirement for diagnostic tests for preeclampsia which will be performed for care, particularly in low- and middle-income countries where access to laboratory facilities could also be limited. There are efforts to develop point-of-care tests which will be utilized in these settings.

Research into the underlying mechanisms of preeclampsia: there's ongoing research into the underlying mechanisms of preeclampsia, including the role of inflammation, oxidative stress, and angiogenesis. This research helps to spot new biomarkers for preeclampsia and potential new targets for treatment.

Collaboration among industry players: There has been increasing collaboration among industry players, academic researchers, and healthcare organizations to develop new diagnostic tests and improve access to existing tests. This collaboration has the potential to accelerate the event of the latest diagnostic tests and improve the general quality of looking after women with preeclampsia.

Preeclampsia Diagnostics Market Key Players:

Some of the key players in the market include:

Abbott: Abbott is a leading provider of diagnostic tests for preeclampsia, including the FreeStyle Libre glucose monitoring system, which can be used to monitor blood glucose levels in pregnant women with gestational diabetes.

Beckman Coulter: A global healthcare company, Beckman Coulter offers a wide range of diagnostic tests for preeclampsia, including the Access PlGF assay and the Access sFlt-1 assay.

GE Healthcare: GE Healthcare offers a variety of diagnostic tools for preeclampsia, including ultrasound systems and fetal monitors.

Hologic: Hologic offers a variety of diagnostic tools for preeclampsia, including ultrasound systems and non-invasive vital sign monitors.

PerkinElmer: PerkinElmer is a global healthcare company that gives a variety of diagnostic tests for preeclampsia, including the DELFIA Xpress PlGF 1-2-3 and DELFIA Xpress sFlt-1 assays.

Roche Diagnostics: Roche Diagnostics is a leading player within the global preeclampsia diagnostics market, offering a variety of diagnostic tests for preeclampsia, including Elecsys PlGF and Elecsys sFlt-1.

Siemens Healthineers: Siemens Healthineers, is a global healthcare company that gives a variety of diagnostic tests for preeclampsia, including blood pressure monitors, ultrasound systems, the Immulite 2000 PlGF assay, and therefore the ADVIA Centaur sFlt-1/PlGF ratio assay.

Thermo Fisher Scientific: Thermo Fisher Scientific is a global biotechnology company that gives a variety of diagnostic tests for preeclampsia, including the BRAHMS sFlt-1 Kryptor assay and therefore the BRAHMS PlGF Kryptor assay.